TOI vs ONCO vs CRVS vs AIOT

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +321. 6%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: CRVS returned -6. 1% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Onconetix, Inc.

(ONCO) is the lower-risk stock at 1. 33β versus PowerFleet, Inc. 's 2. 71β — meaning AIOT is approximately 104% more volatile than ONCO relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 64% for PowerFleet, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to 23. 9% for The Oncology Institute, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corvus Pharmaceuticals, Inc.

(CRVS) is the more profitable company, earning 0. 0% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AIOT (17.

8% yield) pays a dividend. TOI, ONCO, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Onconetix, Inc.

(ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONCO: -100. 0%, CRVS: -6. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TOI (Healthcare) and ONCO (Healthcare) and CRVS (Healthcare) and AIOT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; ONCO is a small-cap quality compounder stock; CRVS is a small-cap quality compounder stock; AIOT is a small-cap income-oriented stock. AIOT pays a dividend while TOI, ONCO, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.